Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimizing Leukemia Relapse: A Phase I, Dose Escalation Study of Decitabine in High Risk Pediatric Leukemia Post Allogeneic Transplant

NCT02264873 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT02264873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02264873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimizing Leukemia Relapse: A Phase I, Dose Escalation Study of Decitabine in High Risk Pediatric Leukemia Post Allogeneic Transplant
Lead sponsor
University of Florida
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
September 18, 2018
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoetic myelodysplasia, leukemia, lymphoblastic, acute, leukemia, myeloid acute